Over the last decade, isocitrate dehydrogenase (IDH) mutations, chromosome 1p/19q deletions, MGMT and TERT promoter methylations, and histone mutations have all served as glioma biomarkers; these markers play key roles in glioma classification and treatment decisions (Chen et al., 2017; Brito et al., 2019). This evidence concerns the gene IDH3A and glioma.